Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.39 USD
+0.05 (3.73%)
Updated Sep 9, 2024 03:59 PM ET
After-Market: $1.39 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Brokerage Reports
Inhibikase Therapeutics, Inc. [IKT]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Update on Phase 2 201 Trial For Risvodetinib Expected at AD/PD Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Outcomes of Pre-NDA Meeting With the FDA for IkT-001Pro
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Risvodetinib (IkT-148009) Receives Orphan Drug Designation For the Treatment of Multiple System Atrophy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Data Announced From 501 Bioequivalence Trial of IkT-001Pro
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
2Q23 Results; Enrollment Ongoing in Phase 2 Trial For IKT-148009 in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Results; First Patient Dosed in Phase 2a Trial in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Results; First Patient Dosed in Phase 2a Trial in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Positive Updates in IkT-148009 Development in Parkinson''s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inhibikase Therapeutics, Inc.
Industry: Medical - Drugs
Moving Forward With a Novel Treatment Candidate for Parkinson''s Disease; Initiating Coverage With a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
|